Calendario›BIVI›NE3107 · SUNRISE-PD
NE3107 · SUNRISE-PD
A Study of NE3107 in Early Parkinson's
Ensayo de BIOVIE INC. en Enfermedad de Parkinson (PD).
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 57
- Centros
- 4
- Fin del objetivo primario
- may 2026
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en mar 2025.
Qué mide
Cociente monocitos-linfocitos (MLR) (12 semanas)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months
Más ensayos de BIVI
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| NE3107 · ADDRESS-LC | Fase 2 | Completado | ago 2026 (real) |
| NE3107 | Fase 3 | Completado | sep 2023 (real) |
| BIV201 continuous infusion | Fase 2 | Interrumpido | may 2023 (real) |
| NE3107 | Fase 1/2 | Completado | nov 2022 (real) |
| Terlipressin acetate continuous… | Fase 2 | Completado | abr 2019 (real) |
Todos los de BIVI, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06757010), actualizada en ago 2026.